PTE - PolarityTE GAAP EPS of -$0.38 misses by $0.06 revenue of $9.4M beats by $1.32M

PolarityTE press release (NASDAQ:PTE): FY GAAP EPS of -$0.38 misses by $0.06. Revenue of $9.4M (-7.2% Y/Y) beats by $1.32M. In the first quarter of 2022, PolarityTE received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for the evaluation of SkinTE® for the treatment of chronic cutaneous ulcers. The company expects to have its first patient treated with SkinTE in April and to have up to 16 sites fully operational by the end of May.

For further details see:

PolarityTE GAAP EPS of -$0.38 misses by $0.06, revenue of $9.4M beats by $1.32M